FATE THERAPEUTICS INC 8-K

What Happened

• Fate Therapeutics Inc. filed a Form 8-K on June 4, 2026 (Item 8.01) announcing that it updated its corporate presentation for use in investor/partner meetings and at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress. The updated slide deck is attached to the filing as Exhibit 99.1 (dated June 4, 2026) and is incorporated by reference.

Key Details

• Filing date: June 4, 2026 (Form 8-K, Item 8.01).
• Exhibit: Corporate Presentation dated June 4, 2026 filed as Exhibit 99.1.
• Use: Presentation intended for meetings and the EULAR 2026 Congress.
• The filing does not include financial statements or report other corporate transactions (Item 9.01 lists the exhibit attachment).

Why It Matters

• This 8-K provides investors with the company’s latest corporate and program presentation material—useful for reviewing current messaging, clinical program highlights, timelines, and strategic priorities as presented by the company at conferences.
• The update itself is a disclosure of presentation materials rather than an earnings or management-change event; investors who want details should review Exhibit 99.1 for any substantive updates to Fate’s programs or guidance.